ScreenerHero

PTNPalatin Technologies, Inc.

Partial data
NAS · US · Healthcare · Biotechnology · palatin.com
10.27USD-11.39%Mkt Cap: 18.27M $P/E: 93.36

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral sma…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$130.53BUSDP/E 30.0
REGN
Regeneron Pharmaceuticals, Inc.
$82.77BUSDP/E 19.9
MRNA
Moderna, Inc.
$72.88BUSD
ARGX
argenx SE
$57.82BUSDP/E 37.5
ARGX
argenx SE
$59.94BUSDP/E 36.7
UCB
UCB SA
$44.25BUSDP/E 18.9
ONC
BeOne Medicines AG
$41.64BUSDP/E 65.8
RVMD
Revolution Medicines, Inc.
$41.34BUSD
RPRX
Royalty Pharma plc
$33.81BUSDP/E 31.5
ALNY
Alnylam Pharmaceuticals, Inc.
$33.67BUSDP/E 43.8
ROIV
Roivant Sciences Ltd.
$27.61BUSD
INSM
Insmed Incorporated
$26.38BUSD
INCY
Incyte Corporation
$25.73BUSDP/E 16.2
BNTX
BioNTech SE
$25.34BUSD
GMAB
Genmab A/S
$21.66BUSDP/E 28.0
GMAB
Genmab A/S
$20.41BUSDP/E 27.6
ASND
Ascendis Pharma A/S
$15.63BUSDP/E 18.5
JAZZ
Jazz Pharmaceuticals plc
$15.62BUSDP/E 16.5
EXEL
Exelixis, Inc.
$14.41BUSDP/E 18.3
SMMT
Summit Therapeutics Inc.
$13.66BUSD

Key Statistics

Company
Market Cap18.27M $
Enterprise Value8.79M $
Revenue (TTM)12.88M $
Gross Profit0 $
Net Income (TTM)-17.31M $
Revenue/Share6.277 USD
Last Price10.27 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)93.36
P/E (Forward)-4.32
PEG1.62
EV/EBITDA-1.00
EV/Revenue0.68
P/S1.45
P/B1.76
EPS (TTM)0.11
EPS (Forward)-2.43
52W Range
5.00020% of range31.00
52W High31.00 USD
52W Low5.000 USD
Profitability
Gross Margin4.28%
Oper. Margin-40.33%
EBITDA Margin-67.93%
Profit Margin-48.50%
ROE362.30%
ROA-529.77%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.31M $
CapEx (TTM)—
FCF Margin-106.12%
FCF Yield-74.83%
Net Debt-9.87M $
Net Debt/EBITDA1.13
Balance Sheet
Debt/Equity-0.03
Current Ratio5.04
Quick Ratio4.86
Book Value/Sh5.963 USD
Cash/Share5.710 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateAug 12, 2025
Analyst Consensus
Rating—
Target (Mean)53.50 USD
Upside (mean)+420.9%
Target Range47.50 USD – 60.00 USD
$47.50+420.9% to mean$60.00
# Analysts3
Ownership
Shares Out.1.78M
Float1.38M
Insiders7.89%
Institutions55.58%
Short Interest
Short Ratio15.6d
Short % Float10.56%
Short % Out.10.52%
Shares Short187.16K
Short (prev mo.)156.33K
Technical
SMA 5014.47 (-29.0%)
SMA 20015.75 (-34.8%)
Beta-0.07
S&P 52W Chg20.11%
Avg Vol (30d)19.27K
Avg Vol (10d)31.83K
Technical Indicators
RSI (14)42.7
MACD-1.2658
MACD Signal-1.3532
MACD Hist.+0.0875
BB Upper15.13 USD
BB Middle12.22 USD
BB Lower9.312 USD
BB Width47.59%
ATR (14)1.140 USD
Vol Ratio (20d)1.25x